Retinal Disease
Advances in AI stand to greatly improve diagnosis, treatment of AMD, but hurdles remain
Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by bias, data quality and limited generalizability, according to a review published in BMJ Open Ophthalmology.
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
The Retina Radar With Dr. Arshad Khanani on Gene Therapy, TKIs, Emerging Treatments, and FDA Trial Guidance
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
In Case You Missed...Evolving Management Protocols for Retinal Diseases
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Community Practice Connections: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
This activity is supported by Regeneron Pharmaceuticals, Inc.
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
In Case You Missed…Translating the Latest Clinical Trial Insights Into Retinal Disease Management
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Researchers identify gene linked to inherited retinal dystrophy
The loss of UBAP1L gene function appears to be associated with nonsyndromic retinal dystrophy, according to research published in JAMA Ophthalmology.